Researchers explored how people aged 16 to 25 years old with inflammatory arthritis evaluate the risks and benefits of treatment. They especially wanted to focus on the patients’ assessments of biologic therapies.
Researchers from Stanford University Medical Center studied patients with inadequate or unacceptable side effects associated with one or more tumor necrosis factor inhibitors or other biologic DMARDs, or both.
The symptoms and pathology of rheumatoid arthritis (RA) worsened in mice models, which were missing the enzyme needed for serotonin synthesis, according to findings published in The American Journal of Pathology.
Researchers treated mice with transforming growth factor β–activated kinase 1 (TAK 1) in order to examine the post-translational modification to TAK 1 and its therapeutic regulation in rheumatoid arthritis. The team used a phytochemical known as epigallocatechin 3 gallate (a compound commonly found in green tea) in a 10-day treatment plan in the mice to study the effects.